利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.054 秒)

    HUMAN B1 CELLS AND USES THEREOF
    5.
    发明申请
    HUMAN B1 CELLS AND USES THEREOF 审中-公开
    人B1细胞及其用途

    公开(公告)号：WO2012040456A2

    公开(公告)日：2012-03-29

    申请号：PCT/US2011/052750

    申请日：2011-09-22

    申请人： THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH ,  ROTHSTEIN, Thomas, L. ,  GRIFFIN, Daniel, O. ,  HOLODICK, Nichol, E.

    发明人： ROTHSTEIN, Thomas, L. ,  GRIFFIN, Daniel, O. ,  HOLODICK, Nichol, E.

    IPC分类号： C12N5/0781

    CPC分类号： C12N5/0635 ,  A61K35/17 ,  A61K39/3955 ,  A61K2035/124 ,  G01N33/564 ,  G01N33/56972 ,  G01N33/57426 ,  G01N33/6893 ,  G01N2333/70507 ,  G01N2333/70553

    摘要： The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b-. The present invention is also directed to a method of isolating human natural immunoglobulin- producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample that express surface biomarkers CD20, CD43 and CD27, and, optionally, CD11b. In addition, the present invention is directed to a methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient having a B1 cell disorder, and treating a patient having a B1 cell disorder.

    摘要翻译： 本发明针对人天然免疫球蛋白产生B1淋巴细胞的分离群体，其中B1淋巴细胞显示表面生物标志物CD20，CD43和CD27，并且是CD11b +或GD11b-。 本发明还涉及从血液样品中分离产生人天然免疫球蛋白的B1淋巴细胞的方法，包括从表达生物标志物CD20，CD43和CD27以及任选的CD11b的样品中分离B淋巴细胞。 此外，本发明涉及用于诊断患者中的B1细胞病症的方法，确定患有B1细胞病症的患者的预后，以及治疗患有B1细胞病症的患者。

    METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    7.
    发明申请
    METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
    治疗慢性淋巴细胞白血病的方法

    公开(公告)号：WO2010151341A1

    公开(公告)日：2010-12-29

    申请号：PCT/US2010/001840

    申请日：2010-06-24

    申请人： THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH ,  CALISSANO, Carlo ,  CHIORAZZI, Nicholas ,  DAMLE, Rajendra, N.

    发明人： CALISSANO, Carlo ,  CHIORAZZI, Nicholas ,  DAMLE, Rajendra, N.

    IPC分类号： A61K39/395

    CPC分类号： G01N33/57426 ,  G01N33/57492

    摘要： The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the "resting re-entry compartment" to treat chronic lymphocytic leukemia in the subject.

    摘要翻译： 本发明提供了治疗患有慢性淋巴细胞性白血病（CLL）的受试者的方法，其包括对受试者施用靶向细胞表面膜抗原的一种或多种试剂，其优先表达在受试者的CLL克隆的增殖性隔室的细胞上以治疗慢性淋巴细胞性白血病 受试者淋巴细胞性白血病。 本发明还提供了一种治疗患有慢性淋巴细胞性白血病的受试者的方法，包括向受试者施用一种或多种靶向表达细胞表面抗原的试剂，优先在“休息再入室”细胞上表达以治疗慢性淋巴细胞性白血病 学科。

    A HISTOCHEMICAL METHOD TO IDENTIFY AND PREDICT DISEASE PROGRESSION OF HUMAN PAPILLOMA VIRUS-INFECTED LESIONS
    8.
    发明申请
    A HISTOCHEMICAL METHOD TO IDENTIFY AND PREDICT DISEASE PROGRESSION OF HUMAN PAPILLOMA VIRUS-INFECTED LESIONS 审中-公开
    鉴定和预测人类斑马鱼病毒感染性疾病进展的组织化学方法

    公开(公告)号：WO2010003072A1

    公开(公告)日：2010-01-07

    申请号：PCT/US2009/049539

    申请日：2009-07-02

    申请人： STATEN ISLAND UNIVERSITY HOSPITAL ,  THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH ,  CASTELLANOS, Mario, R.

    发明人： CASTELLANOS, Mario, R.

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/708

    摘要： The present invention provides a method for distinguishing benign human papilloma virus (HPV)-infected tissue from HPV related lesions that have undergone malignant transformation. The invention comprises a simple histochemical staining method and details a novel process for examining HPV-infected cells by determining susceptibility to enzymatic nuclear digestion. Residual virion associated DNA is seen only in benign HPV-infected lesions, while absence of residual nuclear DNA is seen with malignant transformation. The method can be used to predict biologic behavior of HPV-infected lesions. The invention can improve current cervical cancer screening programs by supplementing histology and cytology, which fail to distinguish transient HPV infection from precancerous cervical lesions. The invention can also improve clinical management of patients by defining malignant potential of HPV-infected tissue more accurately.

    摘要翻译： 本发明提供了一种区分良性人乳头瘤病毒（HPV）感染组织与经历恶性转化的HPV相关病变的方法。 本发明包括简单的组织化学染色方法，并详细描述了通过确定对酶促消化的易感性来检测HPV感染细胞的新方法。 残留的病毒体相关DNA仅在良性HPV感染的病变中见到，而恶性转化则不存在残留的核DNA。 该方法可用于预测HPV感染病变的生物学行为。 本发明可以通过补充组织学和细胞学来改善目前的宫颈癌筛查程序，其不能区分瞬时HPV感染与癌前期宫颈病变。 本发明还可以更准确地定义HPV感染组织的恶性潜能，从而改善患者的临床治疗。

    OXIME DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR
    9.
    发明申请
    OXIME DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR 审中-公开
    OXIME衍生物作为MACROPHAGE MIGRATION INHIBITORY因子的抑制剂

    公开(公告)号：WO2007145888A2

    公开(公告)日：2007-12-21

    申请号：PCT/US2007/013139

    申请日：2007-06-04

    申请人： THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH ,  AL-ABED, Yousef

    发明人： AL-ABED, Yousef

    IPC分类号： A61K31/506

    CPC分类号： C07C291/04 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14

    摘要： Provided are compounds of formula (I) and other compounds. Also provided are pharmaceutical compositions comprising these compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal, and methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock.

    摘要翻译： 提供式（I）化合物和其它化合物。 还提供了包含这些化合物的药物组合物。 此外，提供了哺乳动物抑制巨噬细胞迁移抑制因子（MIF）活性的方法，以及治疗或预防哺乳动物炎症的方法，以及治疗具有败血症，败血病和/或内毒素性休克的哺乳动物的方法。